Wuxi Biologics Stock Performance
| WXIBF Stock | USD 1.86 0.00 0.00% |
On a scale of 0 to 100, WuXi Biologics holds a performance score of 8. The firm maintains a market beta of 0.44, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, WuXi Biologics' returns are expected to increase less than the market. However, during the bear market, the loss of holding WuXi Biologics is expected to be smaller as well. Please check WuXi Biologics' treynor ratio, and the relationship between the standard deviation and kurtosis , to make a quick decision on whether WuXi Biologics' historical returns will revert.
Risk-Adjusted Performance
8 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in WuXi Biologics are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite nearly inconsistent fundamental drivers, WuXi Biologics reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 7.1 B | |
| Total Cashflows From Investing Activities | -9.6 B | |
| Free Cash Flow | -3.1 B |
WuXi |
WuXi Biologics Relative Risk vs. Return Landscape
If you would invest 132.00 in WuXi Biologics on September 3, 2024 and sell it today you would earn a total of 54.00 from holding WuXi Biologics or generate 40.91% return on investment over 90 days. WuXi Biologics is currently producing 0.6904% returns and takes up 6.0896% volatility of returns over 90 trading days. Put another way, 54% of traded pink sheets are less volatile than WuXi, and 87% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
WuXi Biologics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for WuXi Biologics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as WuXi Biologics, and traders can use it to determine the average amount a WuXi Biologics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1134
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | WXIBF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.09 actual daily | 54 54% of assets are less volatile |
Expected Return
| 0.69 actual daily | 13 87% of assets have higher returns |
Risk-Adjusted Return
| 0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average WuXi Biologics is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of WuXi Biologics by adding it to a well-diversified portfolio.
WuXi Biologics Fundamentals Growth
WuXi Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of WuXi Biologics, and WuXi Biologics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on WuXi Pink Sheet performance.
| Return On Equity | 0.12 | |||
| Return On Asset | 0.0551 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.31 % | |||
| Current Valuation | 29.3 B | |||
| Shares Outstanding | 4.22 B | |||
| Price To Earning | 107.74 X | |||
| Price To Book | 5.92 X | |||
| Price To Sales | 2.11 X | |||
| Revenue | 10.29 B | |||
| EBITDA | 4.03 B | |||
| Cash And Equivalents | 9.86 B | |||
| Cash Per Share | 2.36 X | |||
| Total Debt | 640.51 M | |||
| Debt To Equity | 0.12 % | |||
| Book Value Per Share | 8.25 X | |||
| Cash Flow From Operations | 3.43 B | |||
| Earnings Per Share | 0.14 X | |||
| Total Asset | 44.03 B | |||
About WuXi Biologics Performance
By analyzing WuXi Biologics' fundamental ratios, stakeholders can gain valuable insights into WuXi Biologics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if WuXi Biologics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if WuXi Biologics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
WuXi Biologics Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the Peoples Republic of China, North America, Europe, and internationally. The company was incorporated in 2014 and is headquartered in Wuxi, China. Wuxi Biologics is traded on OTC Exchange in the United States.Things to note about WuXi Biologics performance evaluation
Checking the ongoing alerts about WuXi Biologics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for WuXi Biologics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| WuXi Biologics is way too risky over 90 days horizon | |
| WuXi Biologics may become a speculative penny stock | |
| WuXi Biologics appears to be risky and price may revert if volatility continues | |
| About 14.0% of the company outstanding shares are owned by insiders |
- Analyzing WuXi Biologics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether WuXi Biologics' stock is overvalued or undervalued compared to its peers.
- Examining WuXi Biologics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating WuXi Biologics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of WuXi Biologics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of WuXi Biologics' pink sheet. These opinions can provide insight into WuXi Biologics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for WuXi Pink Sheet analysis
When running WuXi Biologics' price analysis, check to measure WuXi Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy WuXi Biologics is operating at the current time. Most of WuXi Biologics' value examination focuses on studying past and present price action to predict the probability of WuXi Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move WuXi Biologics' price. Additionally, you may evaluate how the addition of WuXi Biologics to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |